Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 35

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---

with third parties. There can be no assurances additional capital will be available to secure additional financing, or if available, that
it will be sufficient to meet our needs on favorable terms. If we are unable to raise additional capital in sufficient amounts or on terms
acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates.
If we raise additional funds through the public or private sale of equity or debt financings, it could result in dilution to our existing
stockholders or increased fixed payment obligations and these securities may have rights senior to those of our common stock and could
contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to
incur additional debt, limitations on our ability to acquire, sell or license our intellectual property rights and other operating restrictions
that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial
condition and prospects.

25

Cash Flows

The following table summarizes
our cash flows for the periods indicated:

    Three Months Ended March 31, 
  
    (in thousands) 
    2025  
    2024 
  
    Net cash and cash equivalents (used in) provided by: 

    Operating activities 
    $(6,824) 
    $(7,476)
  
    Financing activities 
     5,274  
     (2,500)
  
    Change in cash and cash equivalents 
     (1,550) 
     (9,976)
  
    Impact on cash from foreign currency translation 
     (35) 
     130 
  
    Cash and cash equivalents, beginning of period 
     20,922  
     35,848 
  
    Cash and cash equivalents, end of period 
    $19,337  
    $26,002 

Operating Activities 

Operating activities used approximately $6.8 million of cash during the three months ended March 31, 2025, and was primarily due to our
loss of $9.7 million, partially offset by non-cash stock-based compensation of $2.1 million and changes in our net operating assets and
liabilities of $0.8 million which is mainly due to an increase in accounts payable and accrued liabilities of $0.7 million.

Operating activities used
approximately $7.5 million of cash during the three months ended March 31,